Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24495602 | 0.89 | HRH3 (0.57) | CYP2D6CYP2C19HRH3PRMT6SMN1; SMN2 | |
| SCHEMBL24061112 | 0.88 | NMT1 (0.57) | HRH3LMNAPOLBDRD4DRD2 | |
| SCHEMBL3425973 | 0.86 | CYP2D6 (0.65) | CYP2D6CYP2C19HRH3PRMT6HRH4 | |
| SCHEMBL24061140 | 0.86 | HRH3 (0.58) | HRH3LMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL23440312 | 0.85 | CYP2D6 (0.68) | CYP2D6CYP2C19HRH3PRMT6HRH4 | |
| SCHEMBL26124226 | 0.84 | CYP2D6 (0.67) | CYP2D6CYP2C19HRH3PRMT6HRH4 | |
| SCHEMBL12613628 | 0.84 | PRMT6 (0.73) | CYP2D6CYP2C19HRH3PRMT6HRH4 | |
| SCHEMBL21206047 | 0.84 | CYP2D6 (0.62) | CYP2D6CYP2C19HRH3PRMT6HRH4 | |
| SCHEMBL26123394 | 0.83 | DRD4 (0.69) | CYP2D6CYP2C19HRH3LMNAALDH1A1 | |
| SCHEMBL16814819 | 0.83 | PRMT6 (0.71) | CYP2D6CYP2C19HRH3PRMT6HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390247-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4257583-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Korea Institute of Science and Technology (KR) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022119090-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 한국과학기술연구원 | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390247-A1 | BIPHENYL PYRROLIDINE AND BIPHENYL DIHYDROIMIDAZOLE DERIVATIVES FOR INHIBITING ACTIVITY OF 5-HT7 SEROTONIN RECEPTOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | HTR7, TPH1, HTR2C | CYP2D6 211/4885CYP2C19 57/4885HRH3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.